Capital expenditure increased 85.9%
Capital expenditure changed +85.9% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
$1.9M→$3.5M6 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →NTCT financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Free-cash-flow proxy decreased 34.0%
Free-cash-flow proxy changed -34.0% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
$71.7M→$47.3M6 prior comparisons
Gross margin moved 211 bp higher
Gross margin changed +211 basis points from the comparable as-filed period.
76.75%→78.86%3 prior comparisons
Gross profit increased 15.8%
Gross profit changed +15.8% from the comparable as-filed period.
$143.3M→$165.9M3 prior comparisons
Inventory increased 60.3%
Inventory changed +60.3% from the comparable as-filed period.
$13.0M→$20.9M3 prior comparisons
Net income increased 693.5%
Net income changed +693.5% from the comparable as-filed period.
-$3.7M→$21.8M3 prior comparisons
Operating cash flow decreased 31.0%
Operating cash flow changed -31.0% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes.
$73.6M→$50.8M6 prior comparisons
Operating income increased 320.6%
Operating income changed +320.6% from the comparable as-filed period.
-$6.6M→$14.5M3 prior comparisons
Operating margin moved 1039 bp higher
Operating margin changed +1039 basis points from the comparable as-filed period.
-3.51%→6.88%3 prior comparisons
Revenue increased 12.7%
Revenue changed +12.7% from the comparable as-filed period.
$186.7M→$210.4M3 prior comparisons
Capex / revenue moved 65 bp higher
Capex / revenue changed +65 basis points from the comparable as-filed period.
1.01%→1.66%2 prior comparisons
Cash & equivalents increased 12.9%
Cash & equivalents changed +12.9% from the comparable as-filed period.
$489.6M→$552.8M2 prior comparisons
Research & development increased 6.4%
Research & development changed +6.4% from the comparable as-filed period.
$39.8M→$42.4M3 prior comparisons
Stock-based compensation decreased 10.0%
Stock-based compensation changed -10.0% from the comparable as-filed period.
$20.0M→$18.0M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.